The AI Saving Time and Lives

Yiannis Kiachopoulos is yet another Greek founder that was ahead of the AI hype. Today, with 12 of the 20 biggest pharma giants relying on his plat- form, Causaly, Yiannis's vision is at the root of life-saving research.

Every great idea starts with a simple "what if?" For Yiannis and his co-founder Artur, it was about teaching a computer to read like The Flash. Being computer scientists and bookworms, the pair dreamt of extracting knowledge at superhuman speeds. They zeroed in on the biomedical domain, a field bursting with millions of publications and crucial to human health. And there they had it: an AI-driven platform that could sift through these vast data troves in seconds, squeezing weeks of research into a mere coffee break.

Fast forward to today, and Causaly is on fire! With a whopping $60 million in Series B fund- ing, the platform is set to redefine the future of drug discovery. The journey of drug development, often spanning over a decade, is being supercharged by Causaly's AI, which helps make sense of the intricate web of disease biology. The platform's hybrid approach, blending a top tier knowledge graph with cutting-edge generative AI, is empowering researchers to make novel discoveries with a tenfold boost in productivity.

From giants like Gilead and Novo Nordisk to regulatory bodies like the FDA, Causaly is becoming the go-to tool for scientific exploration.

In a world where AI often remains a buzzword, Causaly stands as a testament to its real-world impact.